Pyrrolo[2,3-d]pyrimidine compounds
View Patent ↗Described herein is pyrrolo{2,3-d}pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing this compounds, and methods for the preparation of these compounds.
1. A method for treating asthma and other obstructive airway diseases selected from the group consisting of chronic asthma, inveterate asthma, late asthma, airway hyper-responsiveness bronchitis, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, recurrent airway obstruction, and chronic obstruction pulmonary disease in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of formula I:
or a pharmaceutically acceptable salt thereof wherein R 1 is C 1-4 alkyl optionally substituted with hydroxy.
2. The method of claim 1 wherein the therapeutically effective amount is from 0.01 mg/kg of body weight/day to 100 mg/kg of body weight/day.
3. The method of claim 1 wherein the therapeutically effective amount is from 0.1 mg/kg of body weight/day to 10 mg/kg of body weight/day.
4. The method of claim 1 wherein the mammal comprises companion animals.
5. The method of claim 4 wherein the companion animals are dogs, cats, and horses.
6. The method of claim 1 wherein the compound of formula I is administered orally, parenterally, or topically.
7. A method for treating autoimmune diseases, selected from rheumatoid arthritis and alopecia in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of formula I of claim 1 .
8. A method for treating cancer selected from mast cell carcinoma, squamous cell carcinoma, lymphoma, and leukemia in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of formula I of claim 1 .
9. A method for treating inflammatory bowel disease, eosinophilic gastroenteritis, and mastocytosis in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of formula I of claim 1 .
10. The method of claim 1 , 7 , 8 , or 9 wherein R 1 is methyl.